Why The Chinese Corruption Saga Makes GlaxoSmithKline plc A Dicey Pick

Royston Wild explains why legal issues could hamper GlaxoSmithKline plc (LON:GSK)’s investment appeal.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) troubles in China could be set to endure.

Chinese problems continue to mount

Make no mistake: GlaxoSmithKline’s ongoing bribery saga in China shows no signs of disappearing any time soon. Allegations initially emerged in June last year that the company was operating a vast slush fund to bribe doctors with cash and other incentives to massage sales figures. The complexity of the case always made a quick resolution highly unlikely, but the stream of bad news seems to have upped a notch or two in recent weeks.

In May Chinese prosecutors announced that the firm’s former head of Chinese operations, Mark Reilly, would stand trial on corruption ChinaFlagcharges. Shortly afterwards the UK Serious Fraud Office announced that it had “opened a criminal investigation into the commercial practices of GlaxoSmithKline and its subsidiaries.” And the company’s admission last month that it was in possession of a secret sex tape including Reilly and his girlfriend came as a further embarrassment to the firm.

News has since emerged that a British corporate detective and his wife, apparently hired by the firm last year, will be tried in a Chinese closed courtroom in August. Peter Humphrey was detained by authorities last July for illegally acquiring information on private individuals — the investigator was employed by GlaxoSmithKline to investigate a former employee accused of orchestrating a smear campaign, the Financial Times reports.

The business has not been directly implicated in the case, but the timing of the action has raised questions over the true reasons behind the detective’s detention so soon after state investigations were launched. And to muddy the waters further, Humphrey has alleged that GlaxoSmithKline said that it had conducted its own investigations and that claims of corruption in the country were baseless.

Next month’s courtroom battle seems to suggest that Chinese authorities remain set on playing hardball with the company, which has already suffered a huge revenues knock in the country — GlaxoSmithKline warned in October that sales in China had fallen by 61% during July-September And the pharma play saw Pharmaceutical and Vaccines turnover in the country drop by almost a fifth during the first three months of 2014 to £137m.

Accusations of bribery are not confined to China, however, as GlaxoSmithKline is also facing investigations in Poland, Jordan, Lebanon and Iraq. Although actions in these countries will of course not prove as disastrous for the turnover column as in China, these investigations hardly do the firm’s tarnished reputation any favours.

I have previously argued that the importance of GlaxoSmithKline’s suite of market-leading products to the Chinese population would take precedence over any long-term crippling legal action for the firm. But as the case in China becomes more and more lurid and convoluted, and investigations pop up in other geographies, the pharmaceuticals firm could be set for persistent sales troubles for some time to come.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »